Raymond James Trust’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Raymond James Trust’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$1.28M	Buy	12,937 +3,072	+31%	+$302K	0.03%	429
2024 Q2	$915K	Buy	9,865 +838	+9%	+$75.1K	0.02%	499
2024 Q1	$857K	Buy	9,027 +1,000	+12%	+$92.8K	0.02%	508
2023 Q4	$717K	Sell	8,027 -1,043	-11%	-$77.5K	0.02%	552
2023 Q3	$662K	Sell	9,070 -605	-6%	-$48.3K	0.02%	536
2023 Q2	$805K	Buy	9,675 +164	+2%	+$13.7K	0.02%	486
2023 Q1	$725K	Buy	9,511 +946	+11%	+$78.5K	0.02%	496
2022 Q4	$711K	Buy	8,565 +2,024	+31%	+$164K	0.02%	484
2022 Q3	$519K	Buy	6,541 +1,539	+31%	+$130K	0.02%	572
2022 Q2	$371K	Sell	5,002 -195	-4%	-$14.6K	0.01%	703
2022 Q1	$467K	Sell	5,197 -1,609	-24%	-$149K	0.01%	661
2021 Q4	$762K	Hold	6,806	–	–	0.02%	505
2021 Q3	$856K	Buy	6,806 +1,000	+17%	+$129K	0.03%	447
2021 Q2	$786K	Buy	5,806 +900	+18%	+$118K	0.03%	459
2021 Q1	$665K	Sell	4,906 -180	-4%	-$26.9K	0.02%	481
2020 Q4	$716K	Sell	5,086 -1,551	-23%	-$199K	0.03%	432
2020 Q3	$739K	Buy	6,637 +1,250	+23%	+$140K	0.03%	380
2020 Q2	$603K	Sell	5,387 -278	-5%	-$27.4K	0.03%	414
2020 Q1	$439K	Buy	5,665 +127	+2%	+$11.2K	0.03%	432
2019 Q4	$527K	Buy	5,538 +196	+4%	+$17K	0.03%	452
2019 Q3	$407K	Buy	5,342 +542	+11%	+$45K	0.02%	526
2019 Q2	$421K	Sell	4,800 -700	-13%	-$59.7K	0.02%	492
2019 Q1	$498K	Sell	5,500 -1,723	-24%	-$147K	0.03%	425
2018 Q4	$518K	Buy	7,223 +802	+12%	+$64.6K	0.03%	388
2018 Q3	$616K	Buy	6,421 +921	+17%	+$89.3K	0.03%	383
2018 Q2	$524K	Sell	5,500 -1,000	-15%	-$91.9K	0.03%	404
2018 Q1	$570K	Hold	6,500	–	–	0.04%	345
2017 Q4	$552K	Hold	6,500	–	–	0.04%	362
2017 Q3	$563K	Hold	6,500	–	–	0.04%	344
2017 Q2	$502K	Hold	6,500	–	–	0.04%	372
2017 Q1	$451K	Buy	+6,500	New	+$437K	0.03%	391
2016 Q1	–	Sell	-3,000	Closed	-$211K	–	716
2015 Q4	$211K	Buy	+3,000	New	+$205K	0.02%	596
2015 Q3	–	Sell	-4,500	Closed	-$378K	–	654
2015 Q2	$378K	Hold	4,500	–	–	0.04%	379
2015 Q1	$339K	Buy	+4,500	New	+$314K	0.04%	411
2014 Q1	–	Sell	-5,919	Closed	-$257K	–	609
2013 Q4	$257K	Hold	5,919	–	–	0.03%	448
2013 Q3	$255K	Hold	5,919	–	–	0.04%	413
2013 Q2	$206K	Buy	+5,919	New	+$208K	0.03%	451

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Raymond James Trust's XBI Position: Q3 2024 in Review

Raymond James Trust increased its State Street SPDR S&P Biotech ETF (XBI) stake by 31% in Q3 2024, buying an estimated $302K and bringing the position to 12,937 shares worth $1.28M. The position accounts for 0.03% of the portfolio, ranked #429.

Raymond James Trust first reported a position in XBI in Q2 2013 and has held it in 37 quarters since. 769 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

Raymond James Trust held 12,937 shares of State Street SPDR S&P Biotech ETF worth $1.28M as of Q3 2024.
Raymond James Trust bought 3,072 State Street SPDR S&P Biotech ETF shares in Q3 2024, an estimated $302K.
State Street SPDR S&P Biotech ETF made up 0.03% of Raymond James Trust's portfolio in Q3 2024, its #429 holding.
Raymond James Trust first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 37 quarters since.
769 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.